Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review

[Display omitted] •Cabozantinib + nivolumab is a first-line therapy for patients with advanced RCC.•Proper AE management improves safety, prolongs treatment, and may optimize efficacy.•Cabozantinib AEs are managed with prophylaxis, dose modification, and supportive care.•Immune-related AEs may requi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer treatment reviews 2022-02, Vol.103, p.102333-102333, Article 102333
Hauptverfasser: McGregor, Bradley, Mortazavi, Amir, Cordes, Lisa, Salabao, Cristina, Vandlik, Susan, Apolo, Andrea B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Cabozantinib + nivolumab is a first-line therapy for patients with advanced RCC.•Proper AE management improves safety, prolongs treatment, and may optimize efficacy.•Cabozantinib AEs are managed with prophylaxis, dose modification, and supportive care.•Immune-related AEs may require nivolumab dose holds and immunosuppressive therapy.•Providers should be aware of overlapping AEs and how to manage them. Tyrosine kinase inhibitors have been successfully developed in combination with immune checkpoint inhibitors to treat advanced renal cell carcinoma (RCC), further advancing treatment. While safety profiles are generally manageable with combination regimens, overlapping adverse events (AEs) and immune-related AEs can make treatment more complex. The CheckMate 9ER study evaluated the tyrosine kinase inhibitor cabozantinib in combination with the anti-programmed cell death protein-1 antibody nivolumab in patients with previously untreated advanced RCC. Cabozantinib + nivolumab demonstrated superiority over sunitinib for progression-free survival, overall survival, and objective response rate. These outcomes supported the approval of cabozantinib + nivolumab as a first-line therapy for advanced RCC. The safety profile was manageable with prophylaxis, supportive care, dose holds and reductions for cabozantinib, and dose holds and immunosuppressive therapy for nivolumab. This review discusses the safety results of CheckMate 9ER and provides guidance on managing some of the more clinically relevant AEs with a focus on overlapping AEs, including diarrhea, elevated amylase/lipase, hepatotoxicity, dermatologic reactions, fatigue, endocrine disorders, and nephrotoxicity. We discuss AE management strategies (prophylaxis, supportive care, dose modification, and immunosuppressive therapy), and provide recommendations for identifying the causative agent of overlapping AEs and for consulting specialists about organ-specific immune-related AEs. Optimizing AE management can maintain tolerability and should be a priority with cabozantinib + nivolumab treatment.
ISSN:0305-7372
1532-1967
1532-1967
DOI:10.1016/j.ctrv.2021.102333